The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...

With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts ...

BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...

RFK Jr. as HHS head is perhaps President-elect Donald Trump’s most controversial Cabinet pick now that Matt Gaetz has ...

A Reuters report on Friday revealed that FDA researchers have found additional molecular evidence tying blockbuster asthma ...

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...